DXCM vs SENS
DXCM: Dexcom is a leader in continuous glucose monitoring (CGM) technology, providing essential real-time health data for diabetes management and metabolic health. SENS: Senseonics develops implantable continuous glucose monitoring systems that stay under the skin for up to one year, offering diabetes patients longer intervals between sensor replacements than conventional CGM devices.
Side-by-side fundamentals
| Metric | DXCM | SENS | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $71.43 | $4.86 | |
| Market cap as of 2026-07-23 | $28.8B | $260M | |
| P/E as of 2026-07-23 | 31.00 | n/a | |
| PEG as of 2026-07-23 | 1.26 | n/a | |
| Net margin as of 2026-07-23 | +19.3% | -214.2% | DXCM higher |
| Gross margin as of 2026-07-23 | +63.4% | +52.1% | DXCM higher |
| Operating margin as of 2026-07-23 | +21.4% | -212.9% | DXCM higher |
| ROE as of 2026-07-23 | +33.8% | -130.0% | DXCM higher |
| ROA as of 2026-07-23 | +13.4% | -67.2% | DXCM higher |
| Debt / equity as of 2026-07-23 | 0.44 | 1.05 | DXCM lower |
| Revenue growth (YoY) as of 2026-07-23 | +16.1% | +71.9% | SENS higher |
| Revenue CAGR (3y) SEC XBRL | +17.0% | +29.1% | SENS higher |
| Beta as of 2026-07-23 | 1.42 | 0.97 | |
| 1-year return as of 2026-07-22 close | -11.0% | -58.1% | DXCM higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.